New hope for lymphoma patients: targeted drug trial launches
NCT ID NCT07355699
First seen Jan 23, 2026 · Last updated May 25, 2026 · Updated 16 times
Summary
This study tests a drug called orelabrutinib, taken alone or with another antibody, in people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. About 88 participants will receive the drug for 6 cycles, and doctors will monitor their response. This is not a cure, but aims to manage the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.